Illuminating Heavy Metals Testing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Illuminating Heavy Metals Testing
USP <231> Heavy Metals is transitioning toward the incorporation of modern quantitative technologies, but there is still much to be resolved.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 36-42


(ILLUSTRATION: M.MCEVOY IMAGES: CASPER BENSON, DAVID FREUND/GETTY IMAGES)
A stimuli article calling for revised methods for detecting heavy metals impurities in drug substances and drug products has been applauded for addressing an issue long overdue and has prompted much needed discussion (1). While the details of the article replacing the nearly 100-year-old USPNF (231) Heavy Metals General Chapter are debated, industry and regulators are actively keeping an eye on its progress. The final chapter will affect makers of drug substances, finished drug products, and raw materials. Factors under consideration include the types of impurities that should be detected, their acceptance limits, and the analytical tools for quantitative assessment.

Impurity detection has received heightened attention since the scandals involving lead in toys, glycerin contamination with diethylene glycol, adulterated heparin, and melamine in pet food and infant formula. A strong impurities screening approach is especially important as an increasing amount of drug substances and excipients are imported from regions outside of the United States. "When FDA has to confront these big problems, it has to start using all the tools at its disposal. Eventually manufacturers will have to know more about what they buy," says Luciano Virgili, former director of global testing standards at Bristol Meyers Squibb.

Problems with current methodology

The USP ‹231› General Chapter screening methods are outdated, nonspecific, and, for the most part, inefficient. The qualitative wet chemistry techniques convert metals to a sulfide and analysts compare the colors of the sample liquid to a standard preparation to determine whether metallic impurities are present. The chapter contains three methods. Method I is used for substances that yield a colorless liquid preparation and involves only dissolving and diluting the substance. Methods II and III, however, are used for substances that do not yield colorless preparations and involve heating the substance, which may result in the loss of some metals and negatively impact the accuracy of the analysis.

"The way the method is run, you can detect 10 different metals while performing the test," says Gayla Velez, director of analytical services at SGS Northview Labs (Northbrook, IL). "But when USP revised the General Chapter a few years ago and they added a monitor to Method II, we found you couldn't recover most of those metals if you spiked it, and then took it through the digestion process. So what concerns me is that we are doing this test on a day-to-day basis, yet we know that we may be losing some of the metals that we are trying to detect."

Industry analysts have reported difficulty with reagents and achieving results with the monitor solutions and standards (2). Moreover, the methods in the current chapter are nonspecific. "One description of it is hitting two rocks together and hoping it's going to tell you the right answer," says Steve Boyajian, business development manager at Activation Labs (Ancaster, Ontario). "You very rarely, if ever, get a positive result from the current test indicating there is metal above the limit. Even if a problem existed, the current test would not be able to detect it."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here